7,319 Shares in Natera, Inc. (NASDAQ:NTRA) Bought by Orion Portfolio Solutions LLC

Orion Portfolio Solutions LLC purchased a new position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 7,319 shares of the medical research company's stock, valued at approximately $929,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Itau Unibanco Holding S.A. acquired a new stake in Natera in the 2nd quarter valued at about $28,000. Quarry LP lifted its position in shares of Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company's stock valued at $34,000 after buying an additional 190 shares during the last quarter. Covestor Ltd boosted its stake in shares of Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company's stock worth $47,000 after acquiring an additional 95 shares during the period. GAMMA Investing LLC boosted its stake in shares of Natera by 32.7% during the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company's stock worth $55,000 after acquiring an additional 106 shares during the period. Finally, True Wealth Design LLC acquired a new position in shares of Natera during the 3rd quarter worth approximately $57,000. Institutional investors own 99.90% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on NTRA shares. The Goldman Sachs Group raised their price target on Natera from $125.00 to $140.00 and gave the company a "buy" rating in a report on Wednesday, October 16th. Piper Sandler raised their target price on shares of Natera from $150.00 to $200.00 and gave the stock an "overweight" rating in a research note on Monday, November 18th. Robert W. Baird upped their price target on shares of Natera from $120.00 to $160.00 and gave the company an "outperform" rating in a research note on Wednesday, November 13th. Canaccord Genuity Group raised their price objective on shares of Natera from $150.00 to $165.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. Finally, Craig Hallum boosted their price objective on Natera from $121.00 to $157.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $152.67.

Insider Activity at Natera

In other Natera news, CEO Steven Leonard Chapman sold 4,523 shares of Natera stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $130.40, for a total value of $589,799.20. Following the transaction, the chief executive officer now owns 191,163 shares in the company, valued at $24,927,655.20. The trade was a 2.31 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Rowan E. Chapman sold 1,767 shares of the stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $170.24, for a total transaction of $300,814.08. Following the completion of the transaction, the director now directly owns 6,202 shares of the company's stock, valued at $1,055,828.48. This trade represents a 22.17 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 132,963 shares of company stock valued at $21,250,107 over the last three months. 7.60% of the stock is owned by insiders.

Natera Price Performance

Shares of NASDAQ NTRA traded up $4.25 during mid-day trading on Monday, reaching $170.80. The company had a trading volume of 1,378,811 shares, compared to its average volume of 1,330,675. The firm has a market cap of $22.55 billion, a price-to-earnings ratio of -97.05 and a beta of 1.63. The business's 50-day simple moving average is $144.87 and its 200 day simple moving average is $125.09. Natera, Inc. has a one year low of $57.22 and a one year high of $175.63. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.57) by $0.31. The firm had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business's revenue for the quarter was up 63.9% on a year-over-year basis. During the same period in the prior year, the company posted ($0.95) earnings per share. On average, research analysts predict that Natera, Inc. will post -1.61 earnings per share for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.